NCT03591146View on ClinicalTrials.gov

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

January 5, 2019

Study Completion Date

January 14, 2019

Conditions
Inguinal Hernia
Interventions
DRUG

TLC590

TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

DRUG

Naropin

Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL

Trial Locations (1)

84020

JBR Clinical Research, Draper

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY